Bharat Parenterals Ltd.
1,789.00
INR
+58.70
(+3.39%)
ISIN
INE365Y01019
Return %
Stock
S&P 500
1Y
40.16
14.20
3Y
183.97
81.12
5Y
386.74
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Bharatkumar R. Desai
- Full Time Employees
- 404
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Survey No: 144-A Vadodara GU India 391520
- IPO Date
- Mar 21, 2018
- Website
- bplindia.in
- Similar Companies
- Business
- Bharat Parenterals Limited operates as a pharmaceutical company primarily engaged in the manufacturing and marketing of a broad spectrum of pharmaceutical formulations. Established in 1992 and headquartered in Vadodara, Gujarat, India, the company produces over 800 products across more than 20 therapeutic categories. Its product portfolio includes general pharmaceuticals; β-Lactam and cephalosporin products manufactured in dedicated facilities; formulations in the forms of tablets, capsules, liquid orals, ointments, creams, lotions, powders; powdered injections and small volume parenterals supplied in ampoules and vials. The company serves domestic and international markets, exporting to over 15 countries, and is recognized as a WHO GMP and ISO 9001:2015 certified manufacturer. Bharat Parenterals also operates an in-house R&D center approved by the Department of Scientific and Industrial Research (DSIR), specializing in formulation development and analytical method validation, which supports its contract manufacturing services. Its subsidiary, Varenyam Healthcare Private Limited, functions as the domestic marketing arm focusing on niche therapies such as anesthesia and critical care with a dedicated sales force. Recent major developments include the company's strategic acquisition of equity shares in Varenyam Healthcare Private Limited to enhance its presence in niche therapy segments and the securing of a large institutional order valued at approximately $27 million (INR 232 crore) for the supply of high-demand pharmaceutical products over an 18-24 month period. These initiatives reflect Bharat Parenterals' focus on business expansion and sustained growth. The company remains publicly traded on the Bombay Stock Exchange under the ticker BPLPHARMA.BO. Bharat Parenterals continues to leverage its integrated manufacturing capabilities, comprehensive therapeutic offerings, and strategic partnerships to maintain its position as one of the fastest growing pharmaceutical companies in India. Its core operations are supported by three main manufacturing units dedicated separately to general products, β-Lactam/cephalosporin products, and specialized formulations. The company has a workforce exceeding 200 employees and upholds a strong commitment to quality, innovation, and compliance within the pharmaceutical industry. This comprehensive positioning within pharmaceutical manufacturing, combined with recent strategic expansions and substantial order inflows, underlines Bharat Parenterals Limited’s evolution as a significant player in the Indian and international pharmaceutical markets.